Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare rate shifts, dialysis quality scores, and clinical trial liabilities make DaVita’s SEC disclosures some of the most intricate in healthcare. Parsing a 300-page annual report or tracking last-minute 8-K updates can distract from real analysis. Stock Titan solves that problem by converting dense text into plain-English takeaways, so understanding DaVita SEC documents with AI feels effortless.
Whether you need a DaVita annual report 10-K simplified for reimbursement risk, a quick look at the latest DaVita quarterly earnings report 10-Q filing, or an alert on DaVita 8-K material events explained, every disclosure lands here seconds after EDGAR posts. Our platform instantly tags DaVita insider trading Form 4 transactions and streams DaVita Form 4 insider transactions real-time, letting you spot executive moves before the market reacts. AI-powered summaries highlight patient-mix trends, segment margins, and legal contingencies so you can move from document to decision in minutes.
Use these insights to:
- Monitor DaVita executive stock transactions Form 4 ahead of CMS rulings
- Compare dialysis economics with peer benchmarks through our DaVita earnings report filing analysis
- Review the DaVita proxy statement executive compensation to see how incentives align with patient outcomes
David Paul Maughan, Chief Operating Officer of DaVita Inc. (DVA), reported a transaction on 09/22/2025. The filing shows 7,501 shares of common stock were disposed of at a price of $130.16 per share through withholding to satisfy tax obligations. Those withheld shares represent 50% of 17,145 restricted stock units that vested for the reporting person from a grant dated September 22, 2022. After the withholding, the reporting person beneficially owns 122,266 shares. The form was signed by an attorney-in-fact on behalf of the reporting person.
DaVita Inc. director Adam H. Schechter reported a non-derivative acquisition of company stock on 08/15/2025. The filing shows 369 shares were acquired with a reported price of $0, leaving the reporting person with 4,699 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 08/19/2025. No derivative transactions or additional remarks are reported in the filing.
Phyllis R. Yale, a director of DaVita Inc. (DVA), reported acquiring 369 shares of DaVita common stock on 08/15/2025 at a reported price of $0. After the reported transaction she beneficially owned 13,570 shares. The Form 4 was filed as an individual filing for one reporting person and was signed by an attorney-in-fact on 08/19/2025.
DaVita Inc. director Barbara J. Desoer, through an attorney-in-fact, reported acquiring 369 shares of DaVita common stock on 08/15/2025 at no cash price indicated on the form and holds 369 shares directly following the transaction. The filing shows she also has indirect beneficial ownership of 12,659 shares through the Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998. The Form 4 was signed by Stephanie N. Berberich as attorney-in-fact on 08/19/2025.
Insider transaction summary: This Form 4 shows that Jason M. Hollar, a director of DaVita Inc. (DVA), acquired 369 shares of DaVita common stock on 08/15/2025. The reported acquisition is coded as A and lists a price of $0, indicating the shares were received without cash payment (e.g., a grant or similar issuance). After the transaction, Mr. Hollar beneficially owned 5,612 shares. The filing was signed by an attorney-in-fact on 08/19/2025.
DaVita Inc. director Gregory J. Moore acquired 369 shares of DaVita common stock on 08/15/2025 at no reported cash price (Code V). After the transaction he beneficially owned 6,820 shares, held directly. The Form 4 discloses this routine insider purchase; no derivative transactions or additional disclosures are reported in the filing.
Wendy L. Schoppert, a director of DaVita Inc. (DVA), reported acquiring 369 shares of DaVita common stock on 08/15/2025 at a reported price of $0. After the transaction she directly owns 369 shares and indirectly owns 2,525 shares through the Wendy L. Schoppert Revocable Trust. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing shows a routine insider acquisition by a director and discloses the split between direct and indirect beneficial ownership.
Dennis W. Pullin, a director of DaVita Inc. (DVA), reported an acquisition of 369 shares of DaVita common stock on 08/15/2025 under a non-derivative transaction coded as an acquisition. The filing shows the price per share as $0 and states he beneficially owns 1,678 shares following the transaction, held in a direct capacity.
FAQ
What is the current stock price of Davita (DVA)?
What is the market cap of Davita (DVA)?
